ETI 001
Alternative Names: ETI-001Latest Information Update: 12 Apr 2022
At a glance
- Originator Elastrin Therapeutics
- Class Antibodies; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders